Abeona Therapeutics (ABEO) Net Equity Issued and Repurchased (2015 - 2025)

Abeona Therapeutics' Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $10.5 million for Q2 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 196.22% year-over-year to $10.5 million in Q2 2025; TTM through Dec 2025 was $17.3 million, a 11.79% increase from a year earlier, with the FY2025 full-year figure at $17.3 million, up 11.79% from the prior year.
• Net Equity Issued and Repurchased climbed to $10.5 million in Q2 2025 per ABEO's latest filing, from $6.8 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $28.4 million in Q4 2022 and bottomed at -$18.3 million in Q3 2022.
• The 5-year median for Net Equity Issued and Repurchased is $5.4 million (2021), against an average of $4.9 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 7971.31% in 2022; the steepest drop was 55490.91% in 2022.
• Year by year, Net Equity Issued and Repurchased stood at $352000.0 in 2021, then jumped by 7971.31% to $28.4 million in 2022, then tumbled by 72.6% to $7.8 million in 2023, then fell by 29.18% to $5.5 million in 2024, then jumped by 90.48% to $10.5 million in 2025.
• Per Business Quant, the three latest ABEO Net Equity Issued and Repurchased figures stand at $10.5 million (Q2 2025), $6.8 million (Q1 2025), and $5.5 million (Q4 2024).